公开(公告)号：US12247024B2

公开(公告)日：2025-03-11

申请号：US18468636

申请日：2023-09-15

Applicant: Cytokinetics, Inc.

Inventor： Denise Andersen ,  Matthew Pfeiffer ,  Norma Tom ,  Bradley P. Morgan

IPC: C07D413/12

Abstract: Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.

公开(公告)号：US20230083960A1

公开(公告)日：2023-03-16

申请号：US17453761

申请日：2021-11-05

Applicant: Cytokinetics, Inc.

Inventor： Bradley P. MORGAN ,  Chris Evans ,  Pu-Ping Lu ,  Makoto Yamasaki ,  Wenyue Wang ,  Scott Collibee ,  Takuya Makino ,  Kazuyuki Tsuchiya ,  Toshio Kurosaki ,  Susumu Yamaki ,  Eriko Honjo ,  Yuka Koizumi ,  Naoto Katoh ,  Ryuichi Sekioka ,  Ikumi Kuriwaki ,  Denise Andersen

IPC: C07D243/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D405/14 ,  C07D401/12 ,  C07D403/14 ,  C07D519/00 ,  C07D413/12 ,  C07D471/10 ,  C07D417/12 ,  C07D413/08

Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein.
Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

公开(公告)号：US11932631B2

公开(公告)日：2024-03-19

申请号：US17816898

申请日：2022-08-02

Applicant: Cytokinetics, Inc.

Inventor： Denise Andersen ,  Matthew Pfeiffer ,  Norma Tom ,  Bradley P. Morgan

IPC: C07D413/12 ,  C07C255/58

CPC classification number: C07D413/12

Abstract: Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.